Diane's Feed
Aug 30, 2013

Trial date of Nov. 25 set for U.S. challenge to AMR-US Airways merger

WASHINGTON, Aug 30 (Reuters) – A federal judge on Friday set
a tentative Nov. 25 trial date in the U.S. government’s legal
challenge to an American Airlines merger with U.S.
Airways.

Judge Colleen Kollar-Kotelly, who will try the case without
a jury, announced the date at a hearing in U.S. District Court.

Aug 30, 2013

Judge in American/US Airways merger wants trial before March

WASHINGTON (Reuters) – A federal judge said on Friday that the trial of a U.S. government lawsuit to block an American Airlines (AAMRQ.PK: Quote, Profile, Research, Stock Buzz) merger with U.S. Airways Group Inc (LCC.N: Quote, Profile, Research, Stock Buzz) should take place before March, the date sought by the U.S. Justice Department.

U.S. District Judge Colleen Kollar-Kotelly said in open court: “March 3, I think, is too far off. It needs to be a tighter, expedited schedule.”

Aug 28, 2013

U.S. government, two airlines say open to settling merger fight

WASHINGTON (Reuters) – American Airlines AAMRQA.UL, US Airways (LCC.N: Quote, Profile, Research, Stock Buzz) and the U.S. Justice Department said on Wednesday they were open to settling a court fight over whether the two companies should be allowed to merge, but there was no sign of an imminent agreement.

The Justice Department filed a lawsuit in mid-August, asking a federal court to block the deal, which would form the world’s biggest air carrier. The government said the merger would lead to higher prices for customers, while the companies said it would make them more competitive and strengthen the market.

Aug 27, 2013

U.S. asks for March trial in airline merger challenge

WASHINGTON (Reuters) – The U.S. Justice Department asked a federal court on Tuesday to set a March 3 trial date to hear arguments over whether it should stop a planned merger between US Airways (LCC.N: Quote, Profile, Research, Stock Buzz) and American Airlines (AAMRQ.PK: Quote, Profile, Research, Stock Buzz).

The companies had requested a 10-day trial that would begin on November 12.

The Justice Department filed a lawsuit on August 13, asking a federal court to order the companies to abandon plans for a deal to create the world’s largest carrier.

Aug 3, 2013

Obama administration overturns ban on some iPad, iPhones

WASHINGTON (Reuters) – The Obama administration has overturned a U.S. trade panel’s ban on the sale of some older iPhones and iPads, reversing a ruling that had favored Samsung Electronics Co Ltd over Apple Inc in their long-running patent battles.

The U.S. International Trade Commission in June banned the import or sale of the iPhone 4, iPhone 3GS, iPad 3G and iPad 2 3G distributed by AT&T Inc, saying the devices infringed a patent owned by the South Korean electronics giant.

Jul 29, 2013

Experts predict long antitrust road for Omnicom, Publicis

WASHINGTON/BRUSSELS (Reuters) – Publicis (PUBP.PA: Quote, Profile, Research, Stock Buzz) and Omnicom (OMC.N: Quote, Profile, Research, Stock Buzz) will most likely have to shed some assets in order for their mega deal to win approval from regulators in the United States, Europe and 40 other countries where they operate.

The deal would combine the world No. 2 agency, Omnicom, with the No. 3, Publicis, to create the world’s largest agency. The companies have expressed confidence that the transaction will move forward.

Jul 26, 2013

US court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK, July 26 (Reuters) – Teva Pharmaceutical
Industries’ $4 billion-a-year multiple sclerosis drug Copaxone
will lose its patent protection in 2014 rather than 2015 because
of a ruling from a U.S. appeals court on Friday, making it
potentially prey to cheaper generics next May.

The U.S. Court of Appeals for the Federal Circuit issued its
decision in a patent fight that pits Teva against two
teams developing cheaper generic forms of Copaxone: one with
Novartis AG and Momenta Pharmaceuticals Inc
and another between Mylan Inc and Natco Pharma Ltd
.

Jul 26, 2013

US court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK, July 26 (Reuters) – Teva Pharmaceutical
Industries’ $4 billion-a-year multiple sclerosis drug Copaxone
will lose its patent protection in 2014 rather than 2015 because
of a ruling from a U.S. appeals court on Friday, making it
potentially prey to cheaper generics next May.

The U.S. Court of Appeals for the Federal Circuit issued its
decision in a patent fight that pits Teva against two
teams developing cheaper generic forms of Copaxone: one with
Novartis AG and Momenta Pharmaceuticals Inc
and another between Mylan Inc and Natco Pharma Ltd
.

Jul 23, 2013

Supreme Court win boosts fight against drug settlements: FTC

WASHINGTON (Reuters) – A recent U.S. Supreme Court ruling giving regulators the right to sue drugmakers for agreements that delay cheaper generic versions of their products should deter some of the most egregious deals and allow the agency to better fight others, Federal Trade Commission Chairwoman Edith Ramirez told lawmakers on Tuesday.

At issue are deals – often called “pay for delay” – where brand-name drugmakers settle patent infringement lawsuits by paying generic companies to postpone marketing their cheaper versions of the products.

Jul 23, 2013

U.S. Supreme Court win boosts fight against drug settlements -FTC

WASHINGTON, July 23 (Reuters) – A recent U.S. Supreme Court
ruling giving regulators the right to sue drugmakers for
agreements that delay cheaper generic versions of their products
should deter some of the most egregious deals and allow the
agency to better fight others, Federal Trade Commission
Chairwoman Edith Ramirez told lawmakers on Tuesday.

At issue are deals – often called “pay for delay” – where
brand-name drugmakers settle patent infringement lawsuits by
paying generic companies to postpone marketing their cheaper
versions of the products.